Image Credit: Activ-6Study.org
The Tennessee Conservative [By Paula Gomes] –
After official spokesperson William Schaffner, MD, said that there was no proof that ivermectin was helpful as a treatment, Vanderbilt University Medical Center is now conducting an ongoing study to see if Ivermectin and other drugs can be used to treat COVID-19.
In an interview with Health in August, William Schaffner, MD, an infectious disease specialist and professor at the
Vanderbilt University School of Medicine said, “The studies that are rigorous have shown that Ivermectin is not worth the paper it’s written on when it comes to treating COVID-19.”
Ivermectin is a drug that is typically used to treat parasitic infections in both humans and livestock. It is no secret that many Americans have sought out doctors to prescribe Ivermectin off label to treat themselves after contracting COVID-19 or to use as a prophylactic after being in close contact with someone with symptoms.
One Middle Tennessee physician, who wishes to remain anonymous for fear of retribution from the Tennessee Board of Medical Examiners, shared with The Tennessee Conservative that he has prescribed Ivermectin with success in the early stages of COVID-19 to many of his patients.
*** Click Here to Support Conservative Journalism in Tennessee. We can’t cover stories like this without your support!***
In a news release from April, The National Institutes of Health (NIH) announced that they would fund a large, randomized, placebo controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19.
“The ACTIV-6 protocol will explore a pool of up to seven drugs approved by FDA for other conditions — an approach called drug repurposing — and test their safety and effectiveness in treating mild to moderate COVID-19. Because the drugs under consideration already have been tested in humans, repurposing could deliver COVID-19 treatment options sooner. Drugs will be administered orally or by inhaler and will be easy for participants to take at home. Participants will be assigned randomly to receive either a placebo or one of the treatments, which will be sent to them by mail.”
Funding for the study is being provided by the American Rescue Plan Act. NIH’s National Center for Advancing Translational Sciences (NCATS) is overseeing the trial. Vanderbilt Institute for Clinical and Translational Research CTSA Program hub at Vanderbilt University Medical Center in Nashville is serving as the trial’s data coordinating center.
In addition to Ivermectin, the other drugs chosen from the pool of seven under consideration in April are:
- Fluvoxamine – a selective serotonin reuptake inhibitor (SSRI), often prescribed for depression
- Fluticasone – an inhaled steroid commonly prescribed for asthma and chronic obstructive pulmonary disease (COPD)
ACTIV-6 is a nationwide double-blind study expected to enroll nearly 15,000 participants. Tennesseans and all other Americans can participate from anywhere in the United States via the ACTIV-6 website or by calling 833-385-1880.
About the Author: Paula Gomes is a Tennessee resident and contributor to The Tennessee Conservative. You can reach Paula at firstname.lastname@example.org.